98%
921
2 minutes
20
Purpose: To evaluate the effectiveness and safety of combining radiofrequency (RF) ablation and percutaneous osteoplasty (POP) to relieve pain, enhance mobility, and improve the quality of life for patients with malignant pubic metastases.
Materials And Methods: A retrospective analysis was conducted on 29 patients with pain caused by pubic metastases who were treated between January 2014 and April 2024. All patients received RF ablation followed by POP, guided by biplane digital subtraction angiography (DSA) and performed under local anesthesia. The primary outcomes focused on pain reduction assessed by the visual analog scale (VAS), whereas the secondary outcomes included functional improvement evaluated by the Musculoskeletal Tumor Society (MSTS) system and quality of life measured using the Quality of Life Questionnaire-Bone Metastases 22 (QLQ-BM22). Procedure-related adverse events (AEs), survival rates, and Kaplan-Meier analysis were also evaluated during the follow-up period.
Results: All procedures were successfully completed without severe AEs. Significant improvements in VAS, MSTS, and QLQ-BM22 scores were observed postprocedurally (P < .001). Leakage of polymethylmethacrylate occurred in 9 cases (9/29, 31.0%); however, none required additional treatment. During the follow-up period, a total of 12 patients (12/29, 41.4%) died, with the median survival time of 48.0 months (SD ± 13.83).
Conclusions: The combination of RF ablation and POP is a feasible and effective treatment modality for pubic metastases, providing significant pain relief, improved limb function, and enhanced quality of life. This minimally invasive approach is a viable treatment option for patients with advanced cancer and has a low risk of AEs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jvir.2025.04.017 | DOI Listing |
J Food Sci
September 2025
College of Food and Bioengineering, Zhengzhou University of Light Industry, Zhengzhou, China.
Primary agricultural products are closely related to our daily lives, as they serve not only as raw materials for food processing but also as products directly purchased by consumers. These products face the issue of freshness decline and spoilage during both production and consumption. Freshness degradation induces sensory deterioration and nutritional loss and promotes harmful substance accumulation, causing gastrointestinal issues or even endangering life.
View Article and Find Full Text PDFDisabil Rehabil
September 2025
Department of Rehabilitation Sciences and Physiotherapy, University of Leuven, Leuven, Belgium.
Purpose: This study aims to cross-culturally validate the Dutch version of the Lymphedema Symptom Intensity and Distress Survey-Head and Neck version 2.0 (LSIDS-H&N v2.0).
View Article and Find Full Text PDFHealth Qual Life Outcomes
September 2025
Department of Health Policy, Corvinus University of Budapest, 8 Fővám tér, Budapest, H-1093, Hungary.
Pharmacoecon Open
September 2025
Acaster Lloyd Consulting Ltd, Lacon House, 84 Theobalds Rd, London, WC1X 8NL, UK.
Background: Isocitrate dehydrogenase-mutant (mIDH) gliomas are malignant central nervous system tumours. After initial resection, patients with mIDH gliomas with favourable prognosis may live without receiving oncologic treatment for years, but ultimately patients will experience recurrence and require radio- and/or chemotherapy (RT/CT). Cost-utility analyses (CUA) can explore the value of treatments that delay recurrence and initiation of RT/CT.
View Article and Find Full Text PDFInt J Obes (Lond)
September 2025
Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Objectives: This study investigated the cost-effectiveness of an early childhood obesity prevention intervention providing telephone and short message service (SMS) support to mothers of children aged 2-4 years by socioeconomic position (SEP).
Methods: A model-based SEP-specific economic evaluation of the intervention was conducted. SEP-specific intervention costs and effects at age 5 years were derived from the trial data and applied to a cohort of 4- to 5-year-old Australian children.